BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kawanami D, Takashi Y, Muta Y, Oda N, Nagata D, Takahashi H, Tanabe M. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. Front Pharmacol 2021;12:754239. [PMID: 34790127 DOI: 10.3389/fphar.2021.754239] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 González-Juanatey JR, Górriz JL, Ortiz A, Valle A, Soler MJ, Facila L. Cardiorenal benefits of finerenone: protecting kidney and heart. Ann Med 2023;55:502-13. [PMID: 36719097 DOI: 10.1080/07853890.2023.2171110] [Reference Citation Analysis]
2 Zanchi A, Jehle AW, Lamine F, Vogt B, Czerlau C, Bilz S, Seeger H, de Seigneux S. Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology. Swiss Med Wkly 2023;153:40004. [PMID: 36652726 DOI: 10.57187/smw.2023.40004] [Reference Citation Analysis]
3 Górriz JL, González-juanatey JR, Facila L, Soler MJ, Valle A, Ortiz A. Finerenona: completando el abordaje del paciente con enfermedad renal y diabetes. Nefrología 2022. [DOI: 10.1016/j.nefro.2022.09.002] [Reference Citation Analysis]
4 Gaikwad DD, Bangar NS, Apte MM, Gvalani A, Tupe RS. Mineralocorticoid interaction with glycated albumin downregulates NRF - 2 signaling pathway in renal cells: Insights into diabetic nephropathy. Int J Biol Macromol 2022;220:837-51. [PMID: 35987363 DOI: 10.1016/j.ijbiomac.2022.08.095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Schukraft S, Hullin R. Cardiorenal Crosstalk in Patients with Heart Failure. Kidney and Dialysis 2022;2:369-385. [DOI: 10.3390/kidneydial2030033] [Reference Citation Analysis]